{"id":670968,"date":"2023-10-05T16:04:01","date_gmt":"2023-10-05T16:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=670968"},"modified":"2023-10-05T16:04:01","modified_gmt":"2023-10-05T16:04:01","slug":"group-b-streptococcus-market-gearing-up-for-outstanding-expansion-during-the-forecast-period-202332-minervax-aps-gbsnnnn2-pfizer-pf06760805gbs-6","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/group-b-streptococcus-market-gearing-up-for-outstanding-expansion-during-the-forecast-period-202332-minervax-aps-gbsnnnn2-pfizer-pf06760805gbs-6_670968.html","title":{"rendered":"Group B Streptococcus Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Minervax ApS (GBS-NN\/NN2), Pfizer (PF-06760805\/GBS 6)"},"content":{"rendered":"
\n
\"Group<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
Group B Streptococcus Market size in the 7MM is approximately USD 194 million in 2022 it is projected to increase during the forecast period. As per DelveInsight, the Group B Streptococcus Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Group B Streptococcus and the launch of new therapies in the market.<\/div>\n

DelveInsight’s “Group B Streptococcus Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Group B Streptococcus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Group B Streptococcus drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Group B Streptococcus treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Group B Streptococcus: An Overview<\/strong><\/p>\n

Group B strep (streptococcus) is a common bacterium, often carried in the intestines or lower genital tract. The bacterium is usually harmless in healthy adults; however, in newborns, it can cause a serious illness known as Group B Streptococcus (GBS). <\/p>\n

Group B Streptococcus can also cause dangerous infections in adults with certain chronic medical conditions, such as diabetes or liver disease. Also, older adults are at increased risk of illness due to group B strep. Group B Streptococcus infections during pregnancy may lead to preterm labor or if the baby is infected while in the uterus, stillbirth, although pregnant women who tested positive for Group B Streptococcus infection are usually asymptomatic.<\/p>\n

In infants, illness caused by Group B Streptococcus can occur within 6 h of birth (early onset) — or weeks or months after birth (late onset). Fever, low body temperature, difficulty feeding, sluggishness, limpness or weak muscle tone, difficulty breathing, irritability, jitteriness, seizures, rash, and others are some of the signs and symptoms of Group B Streptococcus.<\/p>\n

Many adults carry Group B Streptococcus in their bodies, usually in the bowel, rectum, bladder, or throat, and have no signs or symptoms. In some cases, however, Group B Streptococcus can cause a urinary tract infection or other more serious infections.<\/p>\n

Group B Streptococcus Market Key Facts<\/strong><\/p>\n